BCIQ Profiles

Company Profile Report

U.S. and China clear Phase III of DB102 to treat DLBCL

Denovo Biopharma LLC (San Diego, Calif.) said FDA and China FDA approved an IND to begin the Phase III ENGINE trial of enzastaurin (DB102) to treat diffuse

Read the full 274 word article

How to gain access

Continue reading with a
two-week free trial.